Drospirenone
- Generic Name
- Drospirenone
- Brand Names
- Angeliq 0.25/0.5 28 Day, Beyaz 28 Day, Gianvi 28-day, Jasmiel 28 Day, Lo-zumandimine 28 Day, Loryna, Nextstellis 28 Day, Nikki 28 Day, Ocella 28 Day, Safyral 28 Day, Slynd, Syeda 28 Day, Tydemy 28 Day, Vestura, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zarah, Zumandimine 28 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30O3
- CAS Number
- 67392-87-4
- Unique Ingredient Identifier
- N295J34A25
- Background
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with Ethinyl estradiol. Most recently, it was approved by both Health Canada and the FDA in combination with Estetrol as an oral contraceptive therapy. Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premens...
- Indication
Drospirenone, in combination with ethinyl estradiol or estetrol, is indicated as an oral contraceptive for the prevention of pregnancy. In addition to its use for contraceptive effects, this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorder. The drug has approved indications for combination with estrogens...
- Associated Conditions
- Atrophy of vulva, Moderate to Severe Vasomotor Symptoms, Neural Tube Defects (NTDs), Premenstrual Dysphoric Disorder (PMDD), Vulvo Vaginal Atrophy, Moderate Acne vulgaris
- Associated Therapies
- Contraception, Folate supplementation therapy
Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 16
- Registration Number
- NCT06345586
- Locations
- 🇹ðŸ‡
Chulalongkorn University, Bangkok, Thailand
Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 16
- Registration Number
- NCT06345560
- Locations
- 🇹ðŸ‡
Chulalongkorn University, Bangkok, Thailand
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 46
- Registration Number
- NCT06039826
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
A Study of Milvexian in Healthy Adult Females
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 20
- Registration Number
- NCT05706753
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Insud Pharma
- Target Recruit Count
- 1009
- Registration Number
- NCT05461573
- Locations
- 🇺🇸
Direct Helpers Research Center, Hialeah, Florida, United States
🇺🇸Clinohio Research Services, Columbus, Ohio, United States
🇺🇸Del Sol Research Management, Tucson, Arizona, United States
European Active Surveillance Study (EURAS)
- Conditions
- Interventions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2009-11-20
- Target Recruit Count
- 59510
- Registration Number
- NCT00302848
- Locations
- 🇩🇪
Center for Epidemiology and Health Research, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.